CRIS Current Research Information System

CESCON, MATTEO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 23.580
NA - Nord America 23.370
EU - Europa 15.970
AF - Africa 1.467
SA - Sud America 1.351
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 10
Totale 65.801
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.070
VN - Vietnam 6.921
SG - Singapore 6.236
CN - Cina 5.120
GB - Regno Unito 3.074
IT - Italia 2.831
DE - Germania 2.318
HK - Hong Kong 1.922
SE - Svezia 1.649
NL - Olanda 1.495
IN - India 1.213
FR - Francia 1.045
BR - Brasile 948
RU - Federazione Russa 741
UA - Ucraina 586
IE - Irlanda 567
KR - Corea 470
FI - Finlandia 432
CI - Costa d'Avorio 386
JP - Giappone 382
ZA - Sudafrica 359
TG - Togo 273
CH - Svizzera 221
EE - Estonia 215
SC - Seychelles 187
AR - Argentina 176
PH - Filippine 172
CA - Canada 169
BG - Bulgaria 159
JO - Giordania 138
TH - Thailandia 128
BD - Bangladesh 124
ID - Indonesia 122
AT - Austria 112
NG - Nigeria 111
BE - Belgio 92
PL - Polonia 92
IQ - Iraq 90
TR - Turchia 90
ES - Italia 89
EC - Ecuador 81
MX - Messico 79
PK - Pakistan 74
TW - Taiwan 67
SA - Arabia Saudita 55
AU - Australia 46
UZ - Uzbekistan 45
RO - Romania 43
IR - Iran 40
CL - Cile 33
GR - Grecia 30
HR - Croazia 28
LT - Lituania 28
MY - Malesia 28
MA - Marocco 25
CO - Colombia 24
VE - Venezuela 24
EG - Egitto 23
PE - Perù 23
PY - Paraguay 23
MK - Macedonia 22
AE - Emirati Arabi Uniti 21
KE - Kenya 18
ET - Etiopia 16
TN - Tunisia 16
DZ - Algeria 15
LB - Libano 13
NP - Nepal 13
RS - Serbia 13
CZ - Repubblica Ceca 12
PS - Palestinian Territory 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
CR - Costa Rica 10
SK - Slovacchia (Repubblica Slovacca) 10
AL - Albania 9
OM - Oman 9
PT - Portogallo 9
AZ - Azerbaigian 8
DK - Danimarca 8
IL - Israele 8
JM - Giamaica 8
PA - Panama 8
LK - Sri Lanka 7
GH - Ghana 6
KH - Cambogia 6
NO - Norvegia 6
AM - Armenia 5
BH - Bahrain 5
HU - Ungheria 5
KZ - Kazakistan 5
LU - Lussemburgo 5
NZ - Nuova Zelanda 5
SI - Slovenia 5
SY - Repubblica araba siriana 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
GA - Gabon 4
MM - Myanmar 4
MN - Mongolia 4
Totale 65.710
Salva come PNG Salva come JPEG
Città #
Singapore 4.316
Southend 2.595
Ashburn 2.529
Fairfield 2.420
Hong Kong 1.824
Chandler 1.715
Ho Chi Minh City 1.511
Hanoi 1.220
Woodbridge 1.144
San Jose 1.110
Dong Ket 1.094
Wilmington 954
Houston 941
Seattle 930
Hefei 881
Santa Clara 855
Cambridge 781
Princeton 737
Bologna 669
Kerkrade 651
Ann Arbor 623
Beijing 580
Dublin 565
Boardman 512
Los Angeles 512
Frankfurt am Main 489
Dallas 433
Lauterbourg 414
Abidjan 385
Seoul 379
Helsinki 347
Eygelshoven 338
Jacksonville 325
Tokyo 316
Lomé 273
Westminster 270
Nanjing 268
New York 256
Munich 245
Council Bluffs 232
Berlin 229
Padova 229
Da Nang 226
Haiphong 218
Milan 210
Bern 185
Buffalo 185
Sofia 155
Jinan 141
Redondo Beach 138
Saint Petersburg 134
Amman 131
Guangzhou 131
Florence 130
Shenyang 129
San Diego 127
São Paulo 117
Redmond 107
Rome 105
Delhi 100
Changsha 96
Turin 95
Dearborn 93
Johannesburg 88
Nanchang 88
Hebei 87
Abeokuta 86
Des Moines 86
Shanghai 86
Brussels 85
Chicago 82
Amsterdam 81
Bengaluru 79
Medford 79
Biên Hòa 78
Bremen 73
London 72
The Dalles 72
Hải Dương 69
Phoenix 69
Zhengzhou 68
Can Tho 66
Tianjin 66
Vienna 66
Mülheim 62
Falls Church 59
Jakarta 59
Toronto 59
Falkenstein 58
Hyderabad 57
Olalla 56
Nuremberg 54
Orem 54
Hangzhou 53
Thái Nguyên 52
Bangkok 50
Jiaxing 50
Montreal 50
Thái Bình 49
Norwalk 48
Totale 42.546
Salva come PNG Salva come JPEG
Nome #
[Angiogenic factors and their relation to stage, lymph-node micrometastases and prognosis in patients operated on for gastric cancer] 1.628
The histological assessment of liver fibrosis in grafts from extended criteria donors predicts the outcome after liver transplantation: A retrospective study 642
Hepatobiliary Scintigraphy in the Preoperative Evaluation of Potential Living Liver Donors 497
A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts 390
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study 358
Appraisal of disease-specific benefits of minimally invasiveness in surgery of breast cancer liver metastases 351
SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study 340
Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study 336
Extracorporeal interval support for organ retrieval delivery regional experience with sharing equipe, equipment & expertise to increase conventionally defined as controlled donor pool in time of pandemic 328
TRAPIANTO DI FEGATO CON TROMBOSI PORTALE COMPLETA: ESPERIENZA DI 11 CASI TRATTATI MEDIANTE ANASTOMOSI TRA LA VENA PORTA DEL GRAFT E LA VARICE GASTRICA DEL RICEVENTE 320
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 310
A comprehensive analysis on expected years of life lost due to pancreatic cancer 309
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 303
Adding Liver Stiffness Measurement to the Routine Evaluation of Hepatocellular Carcinoma Resectability Can Optimize Clinical Outcome 301
Molecular Aging of Human Liver: An Epigenetic/Transcriptomic Signature 273
Hypothermic Oxygenated New Machine Perfusion System in Liver and Kidney Transplantation of Extended Criteria Donors:First Italian Clinical Trial 269
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study 268
A new liver transplant priority for patients with hepatocellular carcinoma. 263
Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants 259
Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically. 257
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 257
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 257
Burnout and psychological distress between surgical and non-surgical residents 254
Gut microbiome dynamics and Enterobacterales infection in liver transplant recipients: A prospective observational study 253
Comprehensive surgical intestinal rescue and transplantation program in adult patients: Bologna experience. 246
Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation 246
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis 238
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 238
Machine Learning Pipeline for the Automated Prediction of MicrovascularInvasion in HepatocellularCarcinomas 237
Surgical therapy for hepatolithiasis: a Western experience. 237
The Effect of a Liver Transplant Program on the Outcomes of Resectable Hepatocellular Carcinoma: A Nationwide Multicenter Analysis 234
Causes of early acute graft failure after liver transplantation: analysis of a 17-year single-centre experience. 233
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 230
Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial 229
Lifelong maintenance of composition, function and cellular/subcellular distribution of proteasomes in human liver 227
The peculiar aging of human liver: A geroscience perspective within transplant context 226
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 225
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 223
Use of perfusional angiosonography in liver transplantation and conservative management of post-transplant intra-hepatic pseudo-aneurysm. 221
LncRNAs as novel players in hepatocellular carcinoma recurrence 221
Bacterial translocation in adult small bowel transplantation 219
Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments 219
Combined kidney-liver, heart-liver, and kidney-pancreas transplantations from a single deceased donor. 218
A matched pair analysis of multicenter longterm follow-up after split-liver transplantation with extended right grafts 218
Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation. 217
Average treatment effect of hepatic resection versus locoregional therapies for hepatocellular carcinoma 217
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 216
Combined liver–dual kidney transplant: Role in expanded donors 215
Complex Liver Transplantation Using Venovenous Bypass With an Atypical Placement of the Portal Vein Cannula 214
An explorative data-analysis to support the choice between hepatic resection and radiofrequency ablation in the treatment of hepatocellular carcinoma. 213
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 213
Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation:a management challenge 212
Acute cellular rejection monitoring after interstinal transplant: utility of serologic markers and zoom videoendoscopy as support of conventional biopsy and clinical findings. 211
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 210
Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pre-transplant Radiology 209
Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study) 208
Coping strategies in intestinal transplantation 208
Automatically extracted machine learning features from preoperative CT to early predict microvascular invasion in HCC: the role of the Zone of Transition (ZOT) 208
Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. 207
Associated benign liver tumors in idiopathic granulomatous hepatitis: a case report 207
Studies on immunoproteasome in human liver. Part I: absence in fetuses, presence in normal subjects, and increased levels in chronic active hepatitis and cirrhosis 207
Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. 207
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 207
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network 206
Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. 205
Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center 205
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 204
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 203
Pre-transplant psoas muscle density as a ready-to-use and low-cost predictor of patient survival after liver transplant 202
Liver transplantation for hepatocellular carcinoma: further considerations on selection criteria. 202
Anatomic variations of intrahepatic bile ducts in a European series and meta-analysis of the literature. 202
Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases 202
Italian experience in adult clinical intestinal and multivisceral transplantation: 6 years later. 202
Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. 201
The role of lymphadenectomy for liver tumors. Further considerations on the appropriateness of treatment strategy 199
Conventional split liver transplantation for two adult recipients: a recent experience in a single European center 198
Competing risk analysis on outcome after hepatic resection of hepatocellular carcinoma in cirrhotic patients. 198
Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. 197
Liver allocation for hepatocellular carcinoma: a European Center policy in the pre-MELD era. 196
Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies 195
Conditional survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients. 194
Induction therapy with Alemtuzumab (Campath) in combined liver-kidney transplantation: University of Bologna experience. 193
Combined heart-liver transplantation: A single-center experience 193
Liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical long-term follow-up and pathogenic implications 193
Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? 192
Daclizumab and Alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period. 192
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. 189
Efficacy of MELD score in predicting survival after liver retransplantation. 188
Assessment of perioperative transfusion requirement for cirrhotic patients undergoing elective hepatectomy 188
Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center 188
Impact of preoperative infection on outcome after liver transplantation 188
In Reply 188
Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients. 187
Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. 186
Early and late virological monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients. 186
Hypothermic oxygenated perfusion versus static cold storage for expanded criteria donors in liver and kidney transplantation: Protocol for a single-center randomized controlled trial 186
Can the dropout risk of candidates with hepatocellular carcinoma predict survival after liver transplantation? 185
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 185
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 184
Impact of psychosocial status on liver transplant process 183
Totale 24.799
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.883
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.883
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.405 0 0 0 0 0 0 0 0 0 324 217 1.864
2021/20226.542 496 236 357 521 587 282 163 505 298 405 1.602 1.090
2022/20237.563 722 1.101 385 970 504 612 235 490 1.346 205 575 418
2023/20242.300 196 405 150 218 178 384 108 146 89 175 133 118
2024/20259.962 483 1.363 850 762 1.363 543 717 341 226 792 580 1.942
2025/202625.136 2.155 2.636 2.247 1.746 2.496 2.544 3.621 874 5.129 1.688 0 0
Totale 67.098